Charlie Gayer
About Charlie Gayer
Charlie Gayer is the Chief Commercial Officer at BioCryst, having joined the company in 2015 and promoted in 2020, with extensive experience in rare disease marketing and sales.
Chief Commercial Officer at BioCryst
Charlie Gayer is the Chief Commercial Officer at BioCryst. He joined the company in August 2015 as the Vice President of Global Strategic Marketing and was promoted to his current role in January 2020. Gayer is responsible for overseeing the commercial strategies and operations of the company, particularly focusing on creating opportunities in new markets and ensuring the company's products reach patients who need them.
Career at Talecris and Grifols
Before joining BioCryst, Charlie Gayer held several US and global commercial leadership roles at Talecris. He initially led US alpha-1 antitrypsin deficiency marketing. Later, he expanded his responsibilities to include European sales and marketing. Following the acquisition of Talecris by Grifols in 2011, Gayer led the US marketing team for the combined immune globulin portfolio of both companies, contributing significantly to their commercial success in the rare disease sector.
Professional Experience at GlaxoSmithKline
Charlie Gayer spent six years at GlaxoSmithKline, where he took on various roles in professional marketing, consumer marketing, and sales. This experience provided him with a broad understanding of the pharmaceutical market and honed his skills in marketing and sales strategies, which have been instrumental in his subsequent leadership positions.
Early Career and Consultancy Roles
Gayer began his career as a strategic consultant for biopharmaceutical companies. He also spent three years as a business analyst at Genzyme Corporation, a pioneer in the rare disease sector. These early roles equipped him with a strong foundation in business strategy and market analysis, which have been critical in his leadership positions.
Education Background
Charlie Gayer holds a B.A. in politics from Princeton University, providing him with a strong liberal arts foundation and an understanding of the political landscape, which can influence healthcare regulations and policies. He also earned an M.B.A. from the Fuqua School of Business at Duke University, where he developed advanced skills in business administration and strategic management, essential for his executive roles in the biopharmaceutical industry.